Johanna Hol Fosse

Dr. Johanna Hol Fosse

Norwegian Veterinary Institute
orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Cancer Cell
Verified
Journal Article
Closed access
Anna Rita CantelmoAnna Rita Cantelmo
Anna Rita Cantelmo
LCLena-Christin Conradi
Lena-Christin Conradi
ABAleksandra Brajic
Aleksandra Brajic
JGJermaine Goveia
Jermaine Goveia
JKJoanna Kalucka
Joanna Kalucka
PCPeter Carmeliet
Peter Carmeliet

9 December 2009 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
Johanna Hol FosseJohanna Hol Fosse
Johanna Hol Fosse
LWLinn Wilhelmsen
Linn Wilhelmsen
GHGuttorm Haraldsen
Guttorm Haraldsen
Some human chemokines are stored for regulated secretion in endothelial cells but such sorting has not been described until now in the mouse. Rapid translocation of P-selectin from WPB to the surface of endothelial cells is crucial for early neutrophil recruitment to acute inflammatory lesions. Likewise, the chemokine CXCL8/IL-8 is sorted to WPB in human endothelial cells, but little is known about its functional importance in lack of a suitable animal model. Here, we explored the distribution of the functional IL-8 homologues CXCL1/KC, CXCL2/MIP-2, and CXCL5-6/LIX in resting and inflamed murine vessels by confocal microscopy and paired immunostaining with markers of WPB, discovering that these chemokines did not localize to WPB but displayed a granular pattern in a subset of vessels in healthy skin compatible with sorting to the type 2 endothelial compartment for regulated secretion. Moreover, all chemokines colocalized with VWF and P-selectin in platelets, suggesting that their storage in platelet α-granules might represent an alternative source of rapidly available, neutrophil-recruiting chemokines. In conclusion, WPB appear not to be involved in regulated secretion of chemokines in the mouse, and instead, the possible existence of type 2 granules and the role of platelets in rapid leukocyte adhesion deserve further attention.

24 February 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
Johanna Hol FosseJohanna Hol Fosse
Johanna Hol Fosse
GHGuttorm Haraldsen
Guttorm Haraldsen
KFKnut Falk
Knut Falk
REReidunn Edelmann
Reidunn Edelmann
There are several reasons to consider the role of endothelial cells in COVID-19 and other emerging viral infections. First, severe cases of COVID-19 show a common breakdown of central vascular functions. Second, SARS-CoV-2 replicates in endothelial cells. Third, prior deterioration of vascular function exacerbates disease, as the most common comorbidities of COVID-19 (obesity, hypertension, and diabetes) are all associated with endothelial dysfunction. Importantly, SARS-CoV-2's ability to infect endothelium is shared by many emerging viruses, including henipaviruses, hantavirus, and highly pathogenic avian influenza virus, all specifically targeting endothelial cells. The ability to infect endothelium appears to support generalised dissemination of infection and facilitate the access to certain tissues. The disturbed vascular function observed in severe COVID-19 is also a prominent feature of many other life-threatening viral diseases, underscoring the need to understand how viruses modulate endothelial function. We here review the role of vascular endothelial cells in emerging viral infections, starting with a summary of endothelial cells as key mediators and regulators of vascular and immune responses in health and infection. Next, we discuss endotheliotropism as a possible virulence factor and detail features that regulate viruses' ability to attach to and enter endothelial cells. We move on to review how endothelial cells detect invading viruses and respond to infection, with particular focus on pathways that may influence vascular function and the host immune system. Finally, we discuss how endothelial cell function can be dysregulated in viral disease, either by viral components or as bystander victims of overshooting or detrimental inflammatory and immune responses. Many aspects of how viruses interact with the endothelium remain poorly understood. Considering the diversity of such mechanisms among different emerging viruses allows us to highlight common features that may be of general validity and point out important challenges.

1 July 2015 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
OSOlav Sundnes
Olav Sundnes
WPWojciech Pietka
Wojciech Pietka
TLTamara Loos
Tamara Loos
JSJon Sponheim
Jon Sponheim
ARAndrew L. Rankin
Andrew L. Rankin
DKDenis Khnykin
Denis Khnykin

1 September 2012 in The American Journal of Pathology
Verified
Journal Article
Closed access
ESEirik Sundlisæter
Eirik Sundlisæter
REReidunn J. Edelmann
Reidunn J. Edelmann
Johanna Hol FosseJohanna Hol Fosse
Johanna Hol Fosse
JSJon Sponheim
Jon Sponheim
AKAxel M. Küchler
Axel M. Küchler
GHGuttorm Haraldsen
Guttorm Haraldsen

1 February 2013 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
JPJürgen Pollheimer
Jürgen Pollheimer
JBJohanna Bodin
Johanna Bodin
OSOlav Sundnes
Olav Sundnes
REReidunn J. Edelmann
Reidunn J. Edelmann
SSSigrid S. Skånland
Sigrid S. Skånland
Johanna Hol FosseJohanna Hol Fosse
Johanna Hol Fosse
Objective—: Interleukin (IL)-33 is a nuclear protein that is released from stressed or damaged cells to act as an alarmin. We investigated the effects of IL-33 on endothelial cells, using the prototype IL-1 family member, IL-1β, as a reference. Methods and Results—: Human umbilical vein endothelial cells were stimulated with IL-33 or IL-1β, showing highly similar phosphorylation of signaling molecules, induction of adhesion molecules, and transcription profiles. However, intradermally injected IL-33 elicited significantly less proinflammatory endothelial activation when compared with IL-1β and led us to observe that quiescent endothelial cells (ppRb low p27 high ) were strikingly resistant to IL-33. Accordingly, the IL-33 receptor was preferentially expressed in nonquiescent cells of low-density cultures, corresponding to selective induction of adhesion molecules and chemokines. Multiparameter phosphoflow cytometry confirmed that signaling driven by IL-33 was stronger in nonquiescent cells. Manipulation of nuclear IL-33 expression by siRNA or adenoviral transduction revealed no functional link between nuclear, endogenous IL-33, and exogenous IL-33 responsiveness. Conclusion—: In contrast to other inflammatory cytokines, IL-33 selectively targets nonquiescent endothelial cells. By this novel concept, quiescent cells may remain nonresponsive to a proinflammatory stimulus that concomitantly triggers a powerful response in cells that have been released from contact inhibition.